1 / 7

INFOBIOMED

INFOBIOMED. NoE. WP 6.1 Pharmainformatics. Information Continuum. NHR. CRPS. Pathology. Pathway. Target. Ligand. Ontologies. Evolution. Complex Regional Pain Syndrome. Clinical to Pathway Erasmus/AZ Pathway to Target(s) Erasmus/AZ Target to Approved Drug AZ/IMIM

amal-herring
Télécharger la présentation

INFOBIOMED

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INFOBIOMED NoE WP 6.1 Pharmainformatics Information Continuum NHR CRPS Pathology Pathway Target Ligand Ontologies Evolution

  2. Complex Regional Pain Syndrome • Clinical to Pathway Erasmus/AZ • Pathway to Target(s) Erasmus/AZ • Target to Approved Drug AZ/IMIM • Target/Pathway to New Target Pathway (Erasmus)

  3. CRPS Critical Questions • How many pathways/mechanisms are we talking about? (Erasmus) • Can we associate or differentiate pathways? (Erasmus/AZ)(important to look for non-obvious associations) • Are there approved drugs + ligands in any associated or expanded pathways that could be identified (Erasmus/AZ/IMIM) • Verify in orignal population if drugs are being used – follow up with patients (Erasmus)

  4. CRPS Technical Questions & Gaps • How do we describe a patient? • Time-dependent observations as discrete units • Patient’s history as a discrete unit • Drug/target databases for all members of identified pathways • Pathway dbs need integration, redundancy checks, conflict resolutions, etc. • Ill-defined Pathways – data mining required? • Mixed clinical/literature data sources – best to combine them, but how??

  5. Nuclear Hormone Receptors • Ligand to Target AZ/IMIM • Target to Pathway AZ • Pathway/Target to Gene Erasmus • Genetic variations Erasmus

  6. NHR Critical Questions • Can we identify all relevant pathways? • Can we get enough relevant ligands and priveledged structures? Integration of 3D data when available? • Clinical data – literature first for PPAR compounds on the market? • Are there secondary targets that can be predicted from the structure of all PPAP compounds and how would these present as a phenotype? (Pathway-based hypothesis generation) • Can we associate a phenotype with an adverse event spectrum through a ligand interaction?

  7. NHR Technical Questions and Gaps • Can we link Chemogenomics tools with pathway tools • Can we effectively populate pathway tool – which one and who needs it? • Adverse events – do we need a standard vocabulary? • Are there other sources of data from patients taking PPAR compounds – national patient registers, clinical study populations......? What are the ’standard’ data sources and how can they be accessed and merged?

More Related